Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2Active not recruiting 2Terminated 1Completed 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Genetic Diseases, Inborn 1

Interventions

Specimen Handling 111Magnetic Resonance Spectroscopy 88Carboplatin 58pembrolizumab 57Biopsy 56Cisplatin 51Nivolumab 46Paclitaxel 39Radiotherapy 38Cyclophosphamide 38Gemcitabine 33Dexamethasone 31Radiation 30Bevacizumab 30atezolizumab 27Pemetrexed 27Etoposide 27olaparib 24Lenalidomide 24Doxorubicin 23X-Rays 22Vincristine 22Prednisone 22Leucovorin 22Immunoglobulin G 22Docetaxel 22Disulfides 22venetoclax 21durvalumab 21Rituximab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Alpelisib × 30 days × Clear all
NCT05038735 2026-06-02

EPIK-B5

Novartis

Phase 3 Active not recruiting
210 enrolled
Breast

Breast Neoplasms

NCT05392608 2026-05-22

SEQUEL-Breast

Borstkanker Onderzoek Groep

Phase 2 Active not recruiting
130 enrolled
Breast

Breast Neoplasms, Genetic Diseases, Inborn

Data powered by HemOnc (CC BY 4.0) Colophon âš¡